{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T01:30:17Z","timestamp":1793410217587,"version":"4.5.0"},"reference-count":168,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,2,10]],"date-time":"2021-02-10T00:00:00Z","timestamp":1612915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,2,10]],"date-time":"2021-02-10T00:00:00Z","timestamp":1612915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Gastroenterol Hepatol"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1038\/s41575-020-00404-2","type":"journal-article","created":{"date-parts":[[2021,2,10]],"date-time":"2021-02-10T17:53:00Z","timestamp":1612979580000},"page":"335-347","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":426,"title":["The role of farnesoid X receptor in metabolic diseases, and gastrointestinal and liver cancer"],"prefix":"10.1038","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8876-5099","authenticated-orcid":false,"given":"Lulu","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7990-2140","authenticated-orcid":false,"given":"Frank J.","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,10]]},"reference":[{"key":"404_CR1","doi-asserted-by":"crossref","first-page":"S120","DOI":"10.1194\/jlr.R800026-JLR200","volume":"50","author":"DW Russell","year":"2009","unstructured":"Russell, D. W. Fifty years of advances in bile acid synthesis and metabolism. J. Lipid Res. 50, S120\u2013S125 (2009).","journal-title":"J. Lipid Res."},{"key":"404_CR2","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/cphy.c120023","volume":"3","author":"JY Chiang","year":"2013","unstructured":"Chiang, J. Y. Bile acid metabolism and signaling. Compr. Physiol. 3, 1191\u20131212 (2013).","journal-title":"Compr. Physiol."},{"key":"404_CR3","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.cmet.2016.05.005","volume":"24","author":"A Wahlstrom","year":"2016","unstructured":"Wahlstrom, A., Sayin, S. I., Marschall, H. U. & Backhed, F. Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism. Cell Metab. 24, 41\u201350 (2016).","journal-title":"Cell Metab."},{"key":"404_CR4","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1194\/jlr.R049437","volume":"55","author":"AF Hofmann","year":"2014","unstructured":"Hofmann, A. F. & Hagey, L. R. Key discoveries in bile acid chemistry and biology and their clinical applications: history of the last eight decades. J. Lipid Res. 55, 1553\u20131595 (2014).","journal-title":"J. Lipid Res."},{"key":"404_CR5","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1002\/hep.29325","volume":"66","author":"PA Dawson","year":"2017","unstructured":"Dawson, P. A. Hepatic bile acid uptake in humans and mice: multiple pathways and expanding potential role for gut-liver signaling. Hepatology 66, 1384\u20131386 (2017).","journal-title":"Hepatology"},{"key":"404_CR6","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.mce.2012.05.004","volume":"368","author":"T Matsubara","year":"2013","unstructured":"Matsubara, T., Li, F. & Gonzalez, F. J. FXR signaling in the enterohepatic system. Mol. Cell Endocrinol. 368, 17\u201329 (2013).","journal-title":"Mol. Cell Endocrinol."},{"key":"404_CR7","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/0092-8674(95)90530-8","volume":"81","author":"BM Forman","year":"1995","unstructured":"Forman, B. M. et al. Identification of a nuclear receptor that is activated by farnesol metabolites. Cell 81, 687\u2013693 (1995).","journal-title":"Cell"},{"key":"404_CR8","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1126\/science.284.5418.1362","volume":"284","author":"M Makishima","year":"1999","unstructured":"Makishima, M. et al. Identification of a nuclear receptor for bile acids. Science 284, 1362\u20131365 (1999).","journal-title":"Science"},{"key":"404_CR9","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1126\/science.284.5418.1365","volume":"284","author":"DJ Parks","year":"1999","unstructured":"Parks, D. J. et al. Bile acids: natural ligands for an orphan nuclear receptor. Science 284, 1365\u20131368 (1999).","journal-title":"Science"},{"key":"404_CR10","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S1097-2765(00)80348-2","volume":"3","author":"H Wang","year":"1999","unstructured":"Wang, H., Chen, J., Hollister, K., Sowers, L. C. & Forman, B. M. Endogenous bile acids are ligands for the nuclear receptor FXR\/BAR. Mol. Cell 3, 543\u2013553 (1999).","journal-title":"Mol. Cell"},{"key":"404_CR11","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S1097-2765(00)00051-4","volume":"6","author":"B Goodwin","year":"2000","unstructured":"Goodwin, B. et al. A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol. Cell 6, 517\u2013526 (2000).","journal-title":"Mol. Cell"},{"key":"404_CR12","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1002\/hep.25740","volume":"56","author":"B Kong","year":"2012","unstructured":"Kong, B. et al. Mechanism of tissue-specific farnesoid X receptor in suppressing the expression of genes in bile-acid synthesis in mice. Hepatology 56, 1034\u20131043 (2012).","journal-title":"Hepatology"},{"key":"404_CR13","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1053\/gast.2001.25503","volume":"121","author":"LA Denson","year":"2001","unstructured":"Denson, L. A. et al. The orphan nuclear receptor, shp, mediates bile acid-induced inhibition of the rat bile acid transporter, ntcp. Gastroenterology 121, 140\u2013147 (2001).","journal-title":"Gastroenterology"},{"key":"404_CR14","doi-asserted-by":"crossref","first-page":"28857","DOI":"10.1074\/jbc.M011610200","volume":"276","author":"M Ananthanarayanan","year":"2001","unstructured":"Ananthanarayanan, M., Balasubramanian, N., Makishima, M., Mangelsdorf, D. J. & Suchy, F. J. Human bile salt export pump promoter is transactivated by the farnesoid X receptor\/bile acid receptor. J. Biol. Chem. 276, 28857\u201328865 (2001).","journal-title":"J. Biol. Chem."},{"key":"404_CR15","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.cmet.2013.01.003","volume":"17","author":"SI Sayin","year":"2013","unstructured":"Sayin, S. I. et al. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab. 17, 225\u2013235 (2013).","journal-title":"Cell Metab."},{"key":"404_CR16","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1038\/s41591-018-0222-4","volume":"24","author":"L Sun","year":"2018","unstructured":"Sun, L. et al. Gut microbiota and intestinal FXR mediate the clinical benefits of metformin. Nat. Med. 24, 1919\u20131929 (2018).","journal-title":"Nat. Med."},{"key":"404_CR17","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/S1097-2765(03)00104-7","volume":"11","author":"M Downes","year":"2003","unstructured":"Downes, M. et al. A chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR. Mol. Cell 11, 1079\u20131092 (2003).","journal-title":"Mol. Cell"},{"key":"404_CR18","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1021\/jm025529g","volume":"45","author":"R Pellicciari","year":"2002","unstructured":"Pellicciari, R. et al. 6\u03b1-Ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J. Med. Chem. 45, 3569\u20133572 (2002).","journal-title":"J. Med. Chem."},{"key":"404_CR19","volume":"6","author":"C Jiang","year":"2015","unstructured":"Jiang, C. et al. Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction. Nat. Commun. 6, 10166 (2015).","journal-title":"Nat. Commun."},{"key":"404_CR20","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1053\/j.gastro.2016.08.057","volume":"151","author":"FJ Gonzalez","year":"2016","unstructured":"Gonzalez, F. J., Jiang, C. & Patterson, A. D. An intestinal microbiota-farnesoid X receptor axis modulates metabolic disease. Gastroenterology 151, 845\u2013859 (2016).","journal-title":"Gastroenterology"},{"key":"404_CR21","doi-asserted-by":"crossref","first-page":"6076","DOI":"10.1158\/0008-5472.CAN-16-0787","volume":"76","author":"PT Campbell","year":"2016","unstructured":"Campbell, P. T. et al. Body mass index, waist circumference, diabetes, and risk of liver cancer for US adults. Cancer Res. 76, 6076\u20136083 (2016).","journal-title":"Cancer Res."},{"key":"404_CR22","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1016\/j.ejca.2012.02.063","volume":"48","author":"Y Chen","year":"2012","unstructured":"Chen, Y., Wang, X., Wang, J., Yan, Z. & Luo, J. Excess body weight and the risk of primary liver cancer: an updated meta-analysis of prospective studies. Eur. J. Cancer 48, 2137\u20132145 (2012).","journal-title":"Eur. J. Cancer"},{"key":"404_CR23","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1136\/gutjnl-2013-304701","volume":"62","author":"M Bardou","year":"2013","unstructured":"Bardou, M., Barkun, A. N. & Martel, M. Obesity and colorectal cancer. Gut 62, 933\u2013947 (2013).","journal-title":"Gut"},{"key":"404_CR24","doi-asserted-by":"crossref","first-page":"11039","DOI":"10.1074\/jbc.M510258200","volume":"281","author":"B Cariou","year":"2006","unstructured":"Cariou, B. et al. The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice. J. Biol. Chem. 281, 11039\u201311049 (2006).","journal-title":"J. Biol. Chem."},{"key":"404_CR25","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S0092-8674(00)00062-3","volume":"102","author":"CJ Sinal","year":"2000","unstructured":"Sinal, C. J. et al. Targeted disruption of the nuclear receptor FXR\/BAR impairs bile acid and lipid homeostasis. Cell 102, 731\u2013744 (2000).","journal-title":"Cell"},{"key":"404_CR26","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.2337\/db11-0030","volume":"60","author":"J Prawitt","year":"2011","unstructured":"Prawitt, J. et al. Farnesoid X receptor deficiency improves glucose homeostasis in mouse models of obesity. Diabetes 60, 1861\u20131871 (2011).","journal-title":"Diabetes"},{"key":"404_CR27","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1073\/pnas.0506982103","volume":"103","author":"Y Zhang","year":"2006","unstructured":"Zhang, Y. et al. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc. Natl Acad. Sci. USA 103, 1006\u20131011 (2006).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"404_CR28","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1053\/j.gastro.2014.12.005","volume":"148","author":"GM Hirschfield","year":"2015","unstructured":"Hirschfield, G. M. et al. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. Gastroenterology 148, 751\u2013761 e758 (2015).","journal-title":"Gastroenterology"},{"key":"404_CR29","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1002\/hep.23849","volume":"52","author":"A Milona","year":"2010","unstructured":"Milona, A. et al. Raised hepatic bile acid concentrations during pregnancy in mice are associated with reduced farnesoid X receptor function. Hepatology 52, 1341\u20131349 (2010).","journal-title":"Hepatology"},{"key":"404_CR30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/hep.31265","volume":"72","author":"JH Hoofnagle","year":"2020","unstructured":"Hoofnagle, J. H. FXR agonists as therapy for liver disease. Hepatology 72, 1\u20133 (2020).","journal-title":"Hepatology"},{"key":"404_CR31","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1007\/s40265-016-0616-x","volume":"76","author":"A Markham","year":"2016","unstructured":"Markham, A. & Keam, S. J. Obeticholic acid: first global approval. Drugs 76, 1221\u20131226 (2016).","journal-title":"Drugs"},{"key":"404_CR32","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","volume":"385","author":"BA Neuschwander-Tetri","year":"2015","unstructured":"Neuschwander-Tetri, B. A. et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 385, 956\u2013965 (2015).","journal-title":"Lancet"},{"key":"404_CR33","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1080\/14740338.2017.1343299","volume":"16","author":"D Issa","year":"2017","unstructured":"Issa, D., Wattacheril, J. & Sanyal, A. J. Treatment options for nonalcoholic steatohepatitis\u2013a safety evaluation. Expert Opin. Drug Saf. 16, 903\u2013913 (2017).","journal-title":"Expert Opin. Drug Saf."},{"key":"404_CR34","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1093\/bmb\/ldaa006","volume":"133","author":"RW Chapman","year":"2020","unstructured":"Chapman, R. W. & Lynch, K. D. Obeticholic acid\u2013a new therapy in PBC and NASH. Br. Med. Bull. 133, 95\u2013104 (2020).","journal-title":"Br. Med. Bull."},{"key":"404_CR35","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.jhep.2009.03.025","volume":"51","author":"S Zhang","year":"2009","unstructured":"Zhang, S., Wang, J., Liu, Q. & Harnish, D. C. Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis. J. Hepatol. 51, 380\u2013388 (2009).","journal-title":"J. Hepatol."},{"key":"404_CR36","volume":"11","author":"J Zhou","year":"2020","unstructured":"Zhou, J. et al. SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis. Nat. Commun. 11, 240 (2020).","journal-title":"Nat. Commun."},{"key":"404_CR37","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1002\/cphy.c120007","volume":"2","author":"FJ Gonzalez","year":"2012","unstructured":"Gonzalez, F. J. Nuclear receptor control of enterohepatic circulation. Compr. Physiol. 2, 2811\u20132828 (2012).","journal-title":"Compr. Physiol."},{"key":"404_CR38","doi-asserted-by":"crossref","first-page":"613","DOI":"10.2337\/db16-0663","volume":"66","author":"C Xie","year":"2017","unstructured":"Xie, C. et al. An intestinal farnesoid X receptor-ceramide signaling axis modulates hepatic gluconeogenesis in mice. Diabetes 66, 613\u2013626 (2017).","journal-title":"Diabetes"},{"key":"404_CR39","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.tem.2015.07.006","volume":"26","author":"B Chaurasia","year":"2015","unstructured":"Chaurasia, B. & Summers, S. A. Ceramides - Lipotoxic inducers of metabolic disorders. Trends Endocrinol. Metab. 26, 538\u2013550 (2015).","journal-title":"Trends Endocrinol. Metab."},{"key":"404_CR40","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.nutres.2011.05.004","volume":"31","author":"K Kubota","year":"2011","unstructured":"Kubota, K. et al. Improvements of mean body mass index and body weight in preobese and overweight Japanese adults with black Chinese tea (Pu-Erh) water extract. Nutr. Res. 31, 421\u2013428 (2011).","journal-title":"Nutr. Res."},{"key":"404_CR41","volume":"10","author":"F Huang","year":"2019","unstructured":"Huang, F. et al. Theabrownin from Pu-erh tea attenuates hypercholesterolemia via modulation of gut microbiota and bile acid metabolism. Nat. Commun. 10, 4971 (2019).","journal-title":"Nat. Commun."},{"key":"404_CR42","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/nm.3760","volume":"21","author":"S Fang","year":"2015","unstructured":"Fang, S. et al. Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance. Nat. Med. 21, 159\u2013165 (2015).","journal-title":"Nat. Med."},{"key":"404_CR43","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1002\/hep.29857","volume":"68","author":"P Pathak","year":"2018","unstructured":"Pathak, P. et al. Intestine farnesoid X receptor agonist and the gut microbiota activate G-protein bile acid receptor-1 signaling to improve metabolism. Hepatology 68, 1574\u20131588 (2018).","journal-title":"Hepatology"},{"key":"404_CR44","doi-asserted-by":"crossref","first-page":"11055","DOI":"10.1074\/jbc.M117.784322","volume":"292","author":"P Pathak","year":"2017","unstructured":"Pathak, P. et al. Farnesoid X receptor induces Takeda G-protein receptor 5 cross-talk to regulate bile acid synthesis and hepatic metabolism. J. Biol. Chem. 292, 11055\u201311069 (2017).","journal-title":"J. Biol. Chem."},{"key":"404_CR45","doi-asserted-by":"crossref","first-page":"G554","DOI":"10.1152\/ajpgi.00223.2019","volume":"318","author":"JYL Chiang","year":"2020","unstructured":"Chiang, J. Y. L. & Ferrell, J. M. Bile acid receptors FXR and TGR5 signaling in fatty liver diseases and therapy. Am. J. Physiol. Gastrointest. Liver Physiol. 318, G554\u2013G573 (2020).","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"404_CR46","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms8629","volume":"6","author":"MS Trabelsi","year":"2015","unstructured":"Trabelsi, M. S. et al. Farnesoid X receptor inhibits glucagon-like peptide-1 production by enteroendocrine L cells. Nat. Commun. 6, 7629 (2015).","journal-title":"Nat. Commun."},{"key":"404_CR47","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-56743-x","volume":"10","author":"S Ducastel","year":"2020","unstructured":"Ducastel, S. et al. The nuclear receptor FXR inhibits glucagon-like peptide-1 secretion in response to microbiota-derived short-chain fatty acids. Sci. Rep. 10, 174 (2020).","journal-title":"Sci. Rep."},{"key":"404_CR48","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/s41575-019-0189-8","volume":"16","author":"N Keum","year":"2019","unstructured":"Keum, N. & Giovannucci, E. Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies. Nat. Rev. Gastroenterol. Hepatol. 16, 713\u2013732 (2019).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"404_CR49","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/35094067","volume":"1","author":"R Fodde","year":"2001","unstructured":"Fodde, R., Smits, R. & Clevers, H. APC, signal transduction and genetic instability in colorectal cancer. Nat. Rev. Cancer 1, 55\u201367 (2001).","journal-title":"Nat. Rev. Cancer"},{"key":"404_CR50","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1002\/ijc.26293","volume":"130","author":"S Lax","year":"2012","unstructured":"Lax, S. et al. Expression of the nuclear bile acid receptor\/farnesoid X receptor is reduced in human colon carcinoma compared to nonneoplastic mucosa independent from site and may be associated with adverse prognosis. Int. J. Cancer 130, 2232\u20132239 (2012).","journal-title":"Int. J. Cancer"},{"key":"404_CR51","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1053\/j.gastro.2009.09.060","volume":"138","author":"S Modica","year":"2010","unstructured":"Modica, S. et al. The intestinal nuclear receptor signature with epithelial localization patterns and expression modulation in tumors. Gastroenterology 138, 636\u2013648.E12 (2010).","journal-title":"Gastroenterology"},{"key":"404_CR52","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1023\/B:DDAS.0000034558.78747.98","volume":"49","author":"A De Gottardi","year":"2004","unstructured":"De Gottardi, A. et al. The bile acid nuclear receptor FXR and the bile acid binding protein IBABP are differently expressed in colon cancer. Dig. Dis. Sci. 49, 982\u2013989 (2004).","journal-title":"Dig. Dis. Sci."},{"key":"404_CR53","doi-asserted-by":"crossref","first-page":"236","DOI":"10.3945\/jn.115.216580","volume":"146","author":"OI Selmin","year":"2016","unstructured":"Selmin, O. I. et al. Inactivation of adenomatous polyposis coli reduces bile acid\/farnesoid X receptor expression through Fxr gene CpG methylation in mouse colon tumors and human colon cancer cells. J. Nutr. 146, 236\u2013242 (2016).","journal-title":"J. Nutr."},{"key":"404_CR54","doi-asserted-by":"crossref","first-page":"G48","DOI":"10.1152\/ajpgi.00234.2013","volume":"306","author":"AM Bailey","year":"2014","unstructured":"Bailey, A. M. et al. FXR silencing in human colon cancer by DNA methylation and KRAS signaling. Am. J. Physiol. Gastrointest. Liver Physiol. 306, G48\u2013G58 (2014).","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"404_CR55","doi-asserted-by":"crossref","first-page":"28421","DOI":"10.1074\/jbc.M114.571513","volume":"289","author":"S Modica","year":"2014","unstructured":"Modica, S. et al. Transcriptional regulation of the intestinal nuclear bile acid farnesoid X receptor (FXR) by the caudal-related homeobox 2 (CDX2). J. Biol. Chem. 289, 28421\u201328432 (2014).","journal-title":"J. Biol. Chem."},{"key":"404_CR56","doi-asserted-by":"crossref","first-page":"9589","DOI":"10.1158\/0008-5472.CAN-08-1791","volume":"68","author":"S Modica","year":"2008","unstructured":"Modica, S., Murzilli, S., Salvatore, L., Schmidt, D. R. & Moschetta, A. Nuclear bile acid receptor FXR protects against intestinal tumorigenesis. Cancer Res. 68, 9589\u20139594 (2008).","journal-title":"Cancer Res."},{"key":"404_CR57","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1124\/jpet.108.145409","volume":"328","author":"RR Maran","year":"2009","unstructured":"Maran, R. R. et al. Farnesoid X receptor deficiency in mice leads to increased intestinal epithelial cell proliferation and tumor development. J. Pharmacol. Exp. Ther. 328, 469\u2013477 (2009).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"404_CR58","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/7f401244-ab06-4243-8688-5c987ddca311","volume":"7","author":"Z Peng","year":"2012","unstructured":"Peng, Z., Raufman, J. P. & Xie, G. Src-mediated cross-talk between farnesoid X and epidermal growth factor receptors inhibits human intestinal cell proliferation and tumorigenesis. PLoS ONE 7, e48461 (2012).","journal-title":"PLoS ONE"},{"key":"404_CR59","first-page":"2067","volume":"40","author":"P Qiao","year":"2018","unstructured":"Qiao, P., Li, S., Zhang, H., Yao, L. & Wang, F. Farnesoid X receptor inhibits proliferation of human colorectal cancer cells via the miR135A1\/CCNG2 signaling pathway. Oncol. Rep. 40, 2067\u20132078 (2018).","journal-title":"Oncol. Rep."},{"key":"404_CR60","volume":"11","author":"J Yu","year":"2020","unstructured":"Yu, J. et al. Farnesoid X receptor antagonizes Wnt\/\u03b2-catenin signaling in colorectal tumorigenesis. Cell Death Dis. 11, 640 (2020).","journal-title":"Cell Death Dis."},{"key":"404_CR61","first-page":"459","volume":"43","author":"YJ Lee","year":"2020","unstructured":"Lee, Y. J. et al. The role of nuclear receptor subfamily 1 group H member 4 (NR1H4) in colon cancer cell survival through the regulation of c-Myc stability. Mol. Cell 43, 459\u2013468 (2020).","journal-title":"Mol. Cell"},{"key":"404_CR62","doi-asserted-by":"crossref","first-page":"8529","DOI":"10.1074\/jbc.RA118.004361","volume":"294","author":"Z Peng","year":"2019","unstructured":"Peng, Z., Chen, J., Drachenberg, C. B., Raufman, J. P. & Xie, G. Farnesoid X receptor represses matrix metalloproteinase 7 expression, revealing this regulatory axis as a promising therapeutic target in colon cancer. J. Biol. Chem. 294, 8529\u20138542 (2019).","journal-title":"J. Biol. Chem."},{"key":"404_CR63","doi-asserted-by":"crossref","first-page":"6251","DOI":"10.4049\/jimmunol.0803978","volume":"183","author":"P Vavassori","year":"2009","unstructured":"Vavassori, P., Mencarelli, A., Renga, B., Distrutti, E. & Fiorucci, S. The bile acid receptor FXR is a modulator of intestinal innate immunity. J. Immunol. 183, 6251\u20136261 (2009).","journal-title":"J. Immunol."},{"key":"404_CR64","doi-asserted-by":"crossref","first-page":"102719","DOI":"10.1016\/j.ebiom.2020.102719","volume":"54","author":"RM Gadaleta","year":"2020","unstructured":"Gadaleta, R. M. et al. Fibroblast growth factor 19 modulates intestinal microbiota and inflammation in presence of farnesoid X receptor. EBioMedicine 54, 102719 (2020).","journal-title":"EBioMedicine"},{"key":"404_CR65","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1038\/sj.bjc.6600340","volume":"86","author":"V Costarelli","year":"2002","unstructured":"Costarelli, V. et al. A prospective study of serum bile acid concentrations and colorectal cancer risk in post-menopausal women on the island of Guernsey. Br. J. Cancer 86, 1741\u20131744 (2002).","journal-title":"Br. J. Cancer"},{"key":"404_CR66","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1002\/ijc.30643","volume":"140","author":"H Cao","year":"2017","unstructured":"Cao, H. et al. Secondary bile acid-induced dysbiosis promotes intestinal carcinogenesis. Int. J. Cancer 140, 2545\u20132556 (2017).","journal-title":"Int. J. Cancer"},{"key":"404_CR67","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.mrrev.2004.08.001","volume":"589","author":"H Bernstein","year":"2005","unstructured":"Bernstein, H., Bernstein, C., Payne, C. M., Dvorakova, K. & Garewal, H. Bile acids as carcinogens in human gastrointestinal cancers. Mutat. Res. 589, 47\u201365 (2005).","journal-title":"Mutat. Res."},{"key":"404_CR68","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s00204-011-0648-7","volume":"85","author":"C Bernstein","year":"2011","unstructured":"Bernstein, C. et al. Carcinogenicity of deoxycholate, a secondary bile acid. Arch. Toxicol. 85, 863\u2013871 (2011).","journal-title":"Arch. Toxicol."},{"key":"404_CR69","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1093\/jnci\/djz166","volume":"112","author":"T Kuhn","year":"2020","unstructured":"Kuhn, T. et al. Prediagnostic plasma bile acid levels and colon cancer risk: a prospective study. J. Natl Cancer Inst. 112, 516\u2013524 (2020).","journal-title":"J. Natl Cancer Inst."},{"key":"404_CR70","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1158\/0008-5472.CAN-16-2860","volume":"77","author":"D Dermadi","year":"2017","unstructured":"Dermadi, D. et al. Western diet deregulates bile acid homeostasis, cell proliferation, and tumorigenesis in colon. Cancer Res. 77, 3352\u20133363 (2017).","journal-title":"Cancer Res."},{"key":"404_CR71","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.cell.2019.01.036","volume":"176","author":"T Fu","year":"2019","unstructured":"Fu, T. et al. FXR regulates intestinal cancer stem cell proliferation. Cell 176, 1098\u20131112 e1018 (2019).","journal-title":"Cell"},{"key":"404_CR72","doi-asserted-by":"crossref","first-page":"8856","DOI":"10.1074\/jbc.M306422200","volume":"279","author":"JL Lew","year":"2004","unstructured":"Lew, J. L. et al. The farnesoid X receptor controls gene expression in a ligand- and promoter-selective fashion. J. Biol. Chem. 279, 8856\u20138861 (2004).","journal-title":"J. Biol. Chem."},{"key":"404_CR73","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1093\/carcin\/bgz050","volume":"40","author":"JS Souris","year":"2019","unstructured":"Souris, J. S. et al. A novel mouse model of sporadic colon cancer induced by combination of conditional Apc genes and chemical carcinogen in the absence of Cre recombinase. Carcinogenesis 40, 1376\u20131386 (2019).","journal-title":"Carcinogenesis"},{"key":"404_CR74","doi-asserted-by":"crossref","first-page":"9721","DOI":"10.1158\/0008-5472.CAN-07-2735","volume":"67","author":"T Hinoi","year":"2007","unstructured":"Hinoi, T. et al. Mouse model of colonic adenoma-carcinoma progression based on somatic Apc inactivation. Cancer Res. 67, 9721\u20139730 (2007).","journal-title":"Cancer Res."},{"key":"404_CR75","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.cell.2015.03.053","volume":"161","author":"M van de Wetering","year":"2015","unstructured":"van de Wetering, M. et al. Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell 161, 933\u2013945 (2015).","journal-title":"Cell"},{"key":"404_CR76","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/s41586-020-2193-0","volume":"581","author":"C Campbell","year":"2020","unstructured":"Campbell, C. et al. Bacterial metabolism of bile acids promotes generation of peripheral regulatory T cells. Nature 581, 475\u2013479 (2020).","journal-title":"Nature"},{"key":"404_CR77","volume":"12","author":"EK Kim","year":"2017","unstructured":"Kim, E. K., Cho, J. H., Kim, E. & Kim, Y. J. Ursodeoxycholic acid inhibits the proliferation of colon cancer cells by regulating oxidative stress and cancer stem-like cell growth. PLoS ONE 12, e0181183 (2017).","journal-title":"PLoS ONE"},{"key":"404_CR78","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1080\/01635580701883003","volume":"60","author":"S Khare","year":"2008","unstructured":"Khare, S. et al. Ursodeoxycholic acid suppresses Cox-2 expression in colon cancer: roles of Ras, p38, and CCAAT\/enhancer-binding protein. Nutr. Cancer 60, 389\u2013400 (2008).","journal-title":"Nutr. Cancer"},{"key":"404_CR79","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1093\/jn\/134.2.483","volume":"134","author":"E Im","year":"2004","unstructured":"Im, E. & Martinez, J. D. Ursodeoxycholic acid (UDCA) can inhibit deoxycholic acid (DCA)-induced apoptosis via modulation of EGFR\/Raf-1\/ERK signaling in human colon cancer cells. J. Nutr. 134, 483\u2013486 (2004).","journal-title":"J. Nutr."},{"key":"404_CR80","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1002\/ijc.21365","volume":"118","author":"SA Shah","year":"2006","unstructured":"Shah, S. A., Volkov, Y., Arfin, Q., Abdel-Latif, M. M. & Kelleher, D. Ursodeoxycholic acid inhibits interleukin 1 beta [corrected] and deoxycholic acid-induced activation of NF-\u03baB and AP-1 in human colon cancer cells. Int. J. Cancer 118, 532\u2013539 (2006).","journal-title":"Int. J. Cancer"},{"key":"404_CR81","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1080\/10717540500394935","volume":"13","author":"L Liu","year":"2006","unstructured":"Liu, L., Fishman, M. L., Hicks, K. B., Kende, M. & Ruthel, G. Pectin\/zein beads for potential colon-specific drug delivery: synthesis and in vitro evaluation. Drug Deliv. 13, 417\u2013423 (2006).","journal-title":"Drug Deliv."},{"key":"404_CR82","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1172\/JCI44031","volume":"121","author":"F Yan","year":"2011","unstructured":"Yan, F. et al. Colon-specific delivery of a probiotic-derived soluble protein ameliorates intestinal inflammation in mice through an EGFR-dependent mechanism. J. Clin. Invest. 121, 2242\u20132253 (2011).","journal-title":"J. Clin. Invest."},{"key":"404_CR83","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1208\/s12249-015-0350-9","volume":"16","author":"S Amidon","year":"2015","unstructured":"Amidon, S., Brown, J. E. & Dave, V. S. Colon-targeted oral drug delivery systems: design trends and approaches. AAPS PharmSciTech 16, 731\u2013741 (2015).","journal-title":"AAPS PharmSciTech"},{"key":"404_CR84","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1053\/j.gastro.2007.04.061","volume":"132","author":"HB El-Serag","year":"2007","unstructured":"El-Serag, H. B. & Rudolph, K. L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132, 2557\u20132576 (2007).","journal-title":"Gastroenterology"},{"key":"404_CR85","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/aps.2014.117","volume":"36","author":"XF Huang","year":"2015","unstructured":"Huang, X. F., Zhao, W. Y. & Huang, W. D. FXR and liver carcinogenesis. Acta Pharmacol. Sin. 36, 37\u201343 (2015).","journal-title":"Acta Pharmacol. Sin."},{"key":"404_CR86","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1124\/jpet.111.179390","volume":"338","author":"A Wolfe","year":"2011","unstructured":"Wolfe, A. et al. Increased activation of the Wnt\/\u03b2-catenin pathway in spontaneous hepatocellular carcinoma observed in farnesoid X receptor knockout mice. J. Pharmacol. Exp. Ther. 338, 12\u201321 (2011).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"404_CR87","doi-asserted-by":"crossref","first-page":"G1245","DOI":"10.1152\/ajpgi.00439.2011","volume":"303","author":"H Su","year":"2012","unstructured":"Su, H. et al. Downregulation of nuclear receptor FXR is associated with multiple malignant clinicopathological characteristics in human hepatocellular carcinoma. Am. J. Physiol. Gastrointest. Liver Physiol. 303, G1245\u2013G1253 (2012).","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"404_CR88","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1093\/carcin\/bgl249","volume":"28","author":"I Kim","year":"2007","unstructured":"Kim, I. et al. Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice. Carcinogenesis 28, 940\u2013946 (2007).","journal-title":"Carcinogenesis"},{"key":"404_CR89","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1158\/0008-5472.CAN-06-1078","volume":"67","author":"F Yang","year":"2007","unstructured":"Yang, F. et al. Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor. Cancer Res. 67, 863\u2013867 (2007).","journal-title":"Cancer Res."},{"key":"404_CR90","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1002\/hep4.1263","volume":"2","author":"S Takahashi","year":"2018","unstructured":"Takahashi, S. et al. Role of farnesoid X receptor and bile acids in hepatic tumor development. Hepatol. Commun. 2, 1567\u20131582 (2018).","journal-title":"Hepatol. Commun."},{"key":"404_CR91","doi-asserted-by":"crossref","first-page":"4226","DOI":"10.18632\/oncotarget.2899","volume":"6","author":"X Liu","year":"2015","unstructured":"Liu, X. et al. Farnesoid X receptor associates with beta-catenin and inhibits its activity in hepatocellular carcinoma. Oncotarget 6, 4226\u20134238 (2015).","journal-title":"Oncotarget"},{"key":"404_CR92","doi-asserted-by":"crossref","first-page":"G295","DOI":"10.1152\/ajpgi.00134.2015","volume":"310","author":"B Kong","year":"2016","unstructured":"Kong, B. et al. Mice with hepatocyte-specific FXR deficiency are resistant to spontaneous but susceptible to cholic acid-induced hepatocarcinogenesis. Am. J. Physiol. Gastrointest. Liver Physiol. 310, G295\u2013G302 (2016).","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"404_CR93","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1002\/hep.25788","volume":"56","author":"Y Liang","year":"2012","unstructured":"Liang, Y., Yang, Z. & Zhong, R. Primary biliary cirrhosis and cancer risk: a systematic review and meta-analysis. Hepatology 56, 1409\u20131417 (2012).","journal-title":"Hepatology"},{"key":"404_CR94","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1002\/hep.21287","volume":"44","author":"AS Knisely","year":"2006","unstructured":"Knisely, A. S. et al. Hepatocellular carcinoma in ten children under five years of age with bile salt export pump deficiency. Hepatology 44, 478\u2013486 (2006).","journal-title":"Hepatology"},{"key":"404_CR95","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-11549-7","volume":"7","author":"M Cariello","year":"2017","unstructured":"Cariello, M. et al. Long-term administration of nuclear bile acid receptor FXR agonist prevents spontaneous hepatocarcinogenesis in Abcb4(-\/-) mice. Sci. Rep. 7, 11203 (2017).","journal-title":"Sci. Rep."},{"key":"404_CR96","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1038\/bjc.2015.38","volume":"112","author":"T Kimhofer","year":"2015","unstructured":"Kimhofer, T., Fye, H., Taylor-Robinson, S., Thursz, M. & Holmes, E. Proteomic and metabonomic biomarkers for hepatocellular carcinoma: a comprehensive review. Br. J. Cancer 112, 1141\u20131156 (2015).","journal-title":"Br. J. Cancer"},{"key":"404_CR97","doi-asserted-by":"crossref","DOI":"10.1186\/1476-4598-10-44","volume":"10","author":"M Liao","year":"2011","unstructured":"Liao, M. et al. Role of bile salt in regulating Mcl-1 phosphorylation and chemoresistance in hepatocellular carcinoma cells. Mol. Cancer 10, 44 (2011).","journal-title":"Mol. Cancer"},{"key":"404_CR98","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.celrep.2013.10.030","volume":"5","author":"S Anakk","year":"2013","unstructured":"Anakk, S. et al. Bile acids activate YAP to promote liver carcinogenesis. Cell Rep. 5, 1060\u20131069 (2013).","journal-title":"Cell Rep."},{"key":"404_CR99","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nature12347","volume":"499","author":"S Yoshimoto","year":"2013","unstructured":"Yoshimoto, S. et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature 499, 97\u2013101 (2013).","journal-title":"Nature"},{"key":"404_CR100","doi-asserted-by":"crossref","unstructured":"Ma, C. et al. Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells. Science 360 (2018).","DOI":"10.1126\/science.aan5931"},{"key":"404_CR101","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1002\/hep.30041","volume":"68","author":"B Kong","year":"2018","unstructured":"Kong, B. et al. Fibroblast growth factor 15-dependent and bile acid-independent promotion of liver regeneration in mice. Hepatology 68, 1961\u20131976 (2018).","journal-title":"Hepatology"},{"key":"404_CR102","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s13105-018-0610-8","volume":"74","author":"Q Li","year":"2018","unstructured":"Li, Q. et al. The ileal FGF15\/19 to hepatic FGFR4 axis regulates liver regeneration after partial hepatectomy in mice. J. Physiol. Biochem. 74, 247\u2013260 (2018).","journal-title":"J. Physiol. Biochem."},{"key":"404_CR103","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1210\/me.2010-0142","volume":"24","author":"K Fon Tacer","year":"2010","unstructured":"Fon Tacer, K. et al. Research resource: comprehensive expression atlas of the fibroblast growth factor system in adult mouse. Mol. Endocrinol. 24, 2050\u20132064 (2010).","journal-title":"Mol. Endocrinol."},{"key":"404_CR104","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/hep.24702","volume":"55","author":"SJ Zweers","year":"2012","unstructured":"Zweers, S. J. et al. The human gallbladder secretes fibroblast growth factor 19 into bile: towards defining the role of fibroblast growth factor 19 in the enterobiliary tract. Hepatology 55, 575\u2013583 (2012).","journal-title":"Hepatology"},{"key":"404_CR105","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1002\/hep.22771","volume":"49","author":"FG Schaap","year":"2009","unstructured":"Schaap, F. G., van der Gaag, N. A., Gouma, D. J. & Jansen, P. L. High expression of the bile salt-homeostatic hormone fibroblast growth factor 19 in the liver of patients with extrahepatic cholestasis. Hepatology 49, 1228\u20131235 (2009).","journal-title":"Hepatology"},{"key":"404_CR106","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.ccr.2011.01.040","volume":"19","author":"ET Sawey","year":"2011","unstructured":"Sawey, E. T. et al. Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by oncogenomic screening. Cancer Cell 19, 347\u2013358 (2011).","journal-title":"Cancer Cell"},{"key":"404_CR107","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1002\/hep.27198","volume":"60","author":"SM Ahn","year":"2014","unstructured":"Ahn, S. M. et al. Genomic portrait of resectable hepatocellular carcinomas: implications of RB1 and FGF19 aberrations for patient stratification. Hepatology 60, 1972\u20131982 (2014).","journal-title":"Hepatology"},{"key":"404_CR108","doi-asserted-by":"crossref","first-page":"13575","DOI":"10.18632\/oncotarget.6185","volume":"7","author":"H Zhao","year":"2016","unstructured":"Zhao, H. et al. FGF19 promotes epithelial-mesenchymal transition in hepatocellular carcinoma cells by modulating the GSK3\u03b2\/\u03b2-catenin signaling cascade via FGFR4 activation. Oncotarget 7, 13575\u201313586 (2016).","journal-title":"Oncotarget"},{"key":"404_CR109","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1002\/hep.30951","volume":"71","author":"J Chen","year":"2020","unstructured":"Chen, J. et al. Fibroblast growth factor 19-mediated up-regulation of SYR-related high-mobility group Box 18 promotes hepatocellular carcinoma metastasis by transactivating fibroblast growth factor receptor 4 and Fms-related tyrosine kinase 4. Hepatology 71, 1712\u20131731 (2020).","journal-title":"Hepatology"},{"key":"404_CR110","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1002\/ijc.29287","volume":"136","author":"I Uriarte","year":"2015","unstructured":"Uriarte, I. et al. Ileal FGF15 contributes to fibrosis-associated hepatocellular carcinoma development. Int. J. Cancer 136, 2469\u20132475 (2015).","journal-title":"Int. J. Cancer"},{"key":"404_CR111","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.jhep.2017.01.027","volume":"66","author":"M Zhou","year":"2017","unstructured":"Zhou, M. et al. Mouse species-specific control of hepatocarcinogenesis and metabolism by FGF19\/FGF15. J. Hepatol. 66, 1182\u20131192 (2017).","journal-title":"J. Hepatol."},{"key":"404_CR112","doi-asserted-by":"crossref","first-page":"34606","DOI":"10.18632\/oncotarget.5314","volume":"6","author":"F Guo","year":"2015","unstructured":"Guo, F. et al. FXR induces SOCS3 and suppresses hepatocellular carcinoma. Oncotarget 6, 34606\u201334616 (2015).","journal-title":"Oncotarget"},{"key":"404_CR113","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.jhep.2012.01.029","volume":"57","author":"B Gao","year":"2012","unstructured":"Gao, B., Wang, H., Lafdil, F. & Feng, D. STAT proteins \u2013 key regulators of anti-viral responses, inflammation, and tumorigenesis in the liver. J. Hepatol. 57, 430\u2013441 (2012).","journal-title":"J. Hepatol."},{"key":"404_CR114","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0043044","volume":"7","author":"U Deuschle","year":"2012","unstructured":"Deuschle, U. et al. FXR controls the tumor suppressor NDRG2 and FXR agonists reduce liver tumor growth and metastasis in an orthotopic mouse xenograft model. PLoS ONE 7, e43044 (2012).","journal-title":"PLoS ONE"},{"key":"404_CR115","volume":"14","author":"J He","year":"2015","unstructured":"He, J. et al. Upregulation of microRNA-122 by farnesoid X receptor suppresses the growth of hepatocellular carcinoma cells. Mol. Cancer 14, 163 (2015).","journal-title":"Mol. Cancer"},{"key":"404_CR116","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-35496-z","volume":"8","author":"RM Gadaleta","year":"2018","unstructured":"Gadaleta, R. M. et al. Suppression of hepatic bile acid synthesis by a non-tumorigenic FGF19 analogue protects mice from fibrosis and hepatocarcinogenesis. Sci. Rep. 8, 17210 (2018).","journal-title":"Sci. Rep."},{"key":"404_CR117","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1159\/000488541","volume":"8","author":"HJ Kang","year":"2019","unstructured":"Kang, H. J. et al. Characterization of hepatocellular carcinoma patients with FGF19 amplification assessed by fluorescence in situ hybridization: a large cohort study. Liver Cancer 8, 12\u201323 (2019).","journal-title":"Liver Cancer"},{"key":"404_CR118","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1158\/2159-8290.CD-19-0555","volume":"9","author":"RD Kim","year":"2019","unstructured":"Kim, R. D. et al. First-in-human phase I study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma. Cancer Discov. 9, 1696\u20131707 (2019).","journal-title":"Cancer Discov."},{"key":"404_CR119","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-12629-4","volume":"7","author":"YM Attia","year":"2017","unstructured":"Attia, Y. M., Tawfiq, R. A., Ali, A. A. & Elmazar, M. M. The FXR agonist, obeticholic acid, suppresses HCC proliferation & metastasis: role of IL-6\/STAT3 signalling pathway. Sci. Rep. 7, 12502 (2017).","journal-title":"Sci. Rep."},{"key":"404_CR120","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1053\/j.gastro.2018.04.032","volume":"155","author":"T Liu","year":"2018","unstructured":"Liu, T. et al. Mechanisms of MAFG dysregulation in cholestatic liver injury and development of liver cancer. Gastroenterology 155, 557\u2013571.e14 (2018).","journal-title":"Gastroenterology"},{"key":"404_CR121","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.jhep.2019.06.011","volume":"71","author":"S Al-Dury","year":"2019","unstructured":"Al-Dury, S. et al. Obeticholic acid may increase the risk of gallstone formation in susceptible patients. J. Hepatol. 71, 986\u2013991 (2019).","journal-title":"J. Hepatol."},{"key":"404_CR122","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1053\/j.gastro.2013.05.042","volume":"145","author":"S Mudaliar","year":"2013","unstructured":"Mudaliar, S. et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology 145, 574\u2013582.e1 (2013).","journal-title":"Gastroenterology"},{"key":"404_CR123","doi-asserted-by":"crossref","first-page":"967472","DOI":"10.1155\/2015\/967472","volume":"2015","author":"R Kanthan","year":"2015","unstructured":"Kanthan, R., Senger, J. L., Ahmed, S. & Kanthan, S. C. Gallbladder cancer in the 21st century. J. Oncol. 2015, 967472 (2015).","journal-title":"J. Oncol."},{"key":"404_CR124","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1002\/hep.20718","volume":"41","author":"K Obama","year":"2005","unstructured":"Obama, K. et al. Genome-wide analysis of gene expression in human intrahepatic cholangiocarcinoma. Hepatology 41, 1339\u20131348 (2005).","journal-title":"Hepatology"},{"key":"404_CR125","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.gene.2011.11.028","volume":"493","author":"XY Zhong","year":"2012","unstructured":"Zhong, X. Y. et al. MicroRNA-421 functions as an oncogenic miRNA in biliary tract cancer through down-regulating farnesoid X receptor expression. Gene 493, 44\u201351 (2012).","journal-title":"Gene"},{"key":"404_CR126","doi-asserted-by":"crossref","first-page":"34617","DOI":"10.18632\/oncotarget.8964","volume":"7","author":"W Wang","year":"2016","unstructured":"Wang, W. et al. FXR agonists enhance the sensitivity of biliary tract cancer cells to cisplatin via SHP dependent inhibition of Bcl-xL expression. Oncotarget 7, 34617\u201334629 (2016).","journal-title":"Oncotarget"},{"key":"404_CR127","doi-asserted-by":"crossref","first-page":"35302","DOI":"10.18632\/oncotarget.9181","volume":"7","author":"M Zuo","year":"2016","unstructured":"Zuo, M. et al. RNA sequencing-based analysis of gallbladder cancer reveals the importance of the liver X receptor and lipid metabolism in gallbladder cancer. Oncotarget 7, 35302\u201335312 (2016).","journal-title":"Oncotarget"},{"key":"404_CR128","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/j.bbadis.2017.08.016","volume":"1864","author":"O Erice","year":"2018","unstructured":"Erice, O. et al. Differential effects of FXR or TGR5 activation in cholangiocarcinoma progression. Biochim. Biophy. Acta Mol. Basis Dis. 1864, 1335\u20131344 (2018).","journal-title":"Biochim. Biophy. Acta Mol. Basis Dis."},{"key":"404_CR129","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0210077","volume":"14","author":"S Di Matteo","year":"2019","unstructured":"Di Matteo, S. et al. The FXR agonist obeticholic acid inhibits the cancerogenic potential of human cholangiocarcinoma. PLoS ONE 14, e0210077 (2019).","journal-title":"PLoS ONE"},{"key":"404_CR130","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1158\/1541-7786.MCR-13-0503","volume":"12","author":"E Lozano","year":"2014","unstructured":"Lozano, E. et al. Cocarcinogenic effects of intrahepatic bile acid accumulation in cholangiocarcinoma development. Mol. Cancer Res. 12, 91\u2013100 (2014).","journal-title":"Mol. Cancer Res."},{"key":"404_CR131","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/164_2019_232","volume":"256","author":"C Gege","year":"2019","unstructured":"Gege, C. et al. Ligands: current status and clinical applications. Handb. Exp. Pharmacol. 256, 167\u2013205 (2019).","journal-title":"Handb. Exp. Pharmacol."},{"key":"404_CR132","doi-asserted-by":"crossref","first-page":"9925","DOI":"10.18632\/oncotarget.24066","volume":"9","author":"S Yamada","year":"2018","unstructured":"Yamada, S. et al. Bile acid metabolism regulated by the gut microbiota promotes non-alcoholic steatohepatitis-associated hepatocellular carcinoma in mice. Oncotarget 9, 9925\u20139939 (2018).","journal-title":"Oncotarget"},{"key":"404_CR133","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-019-0406-6","volume":"25","author":"J Wirbel","year":"2019","unstructured":"Wirbel, J. et al. Meta-analysis of fecal metagenomes reveals global microbial signatures that are specific for colorectal cancer. Nat. Med. 25, 679\u2013689 (2019).","journal-title":"Nat. Med."},{"key":"404_CR134","doi-asserted-by":"crossref","first-page":"19909","DOI":"10.1074\/jbc.M207903200","volume":"278","author":"F Chen","year":"2003","unstructured":"Chen, F. et al. Liver receptor homologue-1 mediates species- and cell line-specific bile acid-dependent negative feedback regulation of the apical sodium-dependent bile acid transporter. J. Biol. Chem. 278, 19909\u201319916 (2003).","journal-title":"J. Biol. Chem."},{"key":"404_CR135","doi-asserted-by":"crossref","first-page":"G912","DOI":"10.1152\/ajpgi.00479.2005","volume":"290","author":"T Frankenberg","year":"2006","unstructured":"Frankenberg, T. et al. Regulation of the mouse organic solute transporter \u03b1-\u03b2, Ost\u03b1-Ost\u03b2, by bile acids. Am. J. Physiol. Gastrointest. Liver Physiol. 290, G912\u2013G922 (2006).","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"404_CR136","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.cmet.2005.09.001","volume":"2","author":"T Inagaki","year":"2005","unstructured":"Inagaki, T. et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab. 2, 217\u2013225 (2005).","journal-title":"Cell Metab."},{"key":"404_CR137","doi-asserted-by":"crossref","first-page":"29749","DOI":"10.1074\/jbc.274.42.29749","volume":"274","author":"J Grober","year":"1999","unstructured":"Grober, J. et al. Identification of a bile acid-responsive element in the human ileal bile acid-binding protein gene. Involvement of the farnesoid X receptor\/9-cis-retinoic acid receptor heterodimer. J. Biol. Chem. 274, 29749\u201329754 (1999).","journal-title":"J. Biol. Chem."},{"key":"404_CR138","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1021\/mp060010s","volume":"3","author":"G Zollner","year":"2006","unstructured":"Zollner, G., Marschall, H. U., Wagner, M. & Trauner, M. Role of nuclear receptors in the adaptive response to bile acids and cholestasis: pathogenetic and therapeutic considerations. Mol. Pharm. 3, 231\u2013251 (2006).","journal-title":"Mol. Pharm."},{"key":"404_CR139","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1053\/j.gastro.2007.05.015","volume":"133","author":"SW Van Mil","year":"2007","unstructured":"Van Mil, S. W. et al. Functional variants of the central bile acid sensor FXR identified in intrahepatic cholestasis of pregnancy. Gastroenterology 133, 507\u2013516 (2007).","journal-title":"Gastroenterology"},{"key":"404_CR140","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s12072-010-9202-6","volume":"4","author":"ZX Yang","year":"2010","unstructured":"Yang, Z. X., Shen, W. & Sun, H. Effects of nuclear receptor FXR on the regulation of liver lipid metabolism in patients with non-alcoholic fatty liver disease. Hepatol. Int. 4, 741\u2013748 (2010).","journal-title":"Hepatol. Int."},{"key":"404_CR141","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1093\/toxsci\/kfx094","volume":"158","author":"S Takahashi","year":"2017","unstructured":"Takahashi, S. et al. Farnesoid X receptor protects against low-dose carbon tetrachloride-induced liver injury through the taurocholate-JNK pathway. Toxicol. Sci. 158, 334\u2013346 (2017).","journal-title":"Toxicol. Sci."},{"key":"404_CR142","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1053\/j.gastro.2004.08.001","volume":"127","author":"S Fiorucci","year":"2004","unstructured":"Fiorucci, S. et al. The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. Gastroenterology 127, 1497\u20131512 (2004).","journal-title":"Gastroenterology"},{"key":"404_CR143","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1124\/jpet.105.084905","volume":"314","author":"S Fiorucci","year":"2009","unstructured":"Fiorucci, S. et al. A farnesoid X receptor-small heterodimer partner regulatory cascade modulates tissue metalloproteinase inhibitor-1 and matrix metalloprotease expression in hepatic stellate cells and promotes resolution of liver fibrosis. J. Pharmacol. Exp. Ther. 314, 584\u2013595 (2009).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"404_CR144","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.bbrc.2013.11.057","volume":"443","author":"WB Wu","year":"2014","unstructured":"Wu, W. B. et al. Activation of farnesoid X receptor attenuates hepatic injury in a murine model of alcoholic liver disease. Biochem. Bioph Res. Co. 443, 68\u201373 (2014).","journal-title":"Biochem. Bioph Res. Co."},{"key":"404_CR145","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.redox.2014.08.007","volume":"2","author":"S Manley","year":"2014","unstructured":"Manley, S. et al. Farnesoid X receptor regulates forkhead Box O3a activation in ethanol-induced autophagy and hepatotoxicity. Redox Biol. 2, 991\u20131002 (2014).","journal-title":"Redox Biol."},{"key":"404_CR146","volume":"5","author":"W Lu","year":"2015","unstructured":"Lu, W. et al. FXR antagonism of NSAIDs contributes to drug-induced liver injury identified by systems pharmacology approach. Sci. Rep. 5, 8114 (2015).","journal-title":"Sci. Rep."},{"key":"404_CR147","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.bbadis.2010.12.006","volume":"1812","author":"WD Chen","year":"2011","unstructured":"Chen, W. D., Wang, Y. D., Meng, Z., Zhang, L. & Huang, W. Nuclear bile acid receptor FXR in the hepatic regeneration. Biochim. Biophys. Acta 1812, 888\u2013892 (2011).","journal-title":"Biochim. Biophys. Acta"},{"key":"404_CR148","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1136\/gut.2010.212159","volume":"60","author":"RM Gadaleta","year":"2011","unstructured":"Gadaleta, R. M. et al. Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. Gut 60, 463\u2013472 (2011).","journal-title":"Gut"},{"key":"404_CR149","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1172\/JCI76738","volume":"125","author":"CT Jiang","year":"2015","unstructured":"Jiang, C. T. et al. Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease. J. Clin. Invest. 125, 386\u2013402 (2015).","journal-title":"J. Clin. Invest."},{"key":"404_CR150","doi-asserted-by":"crossref","first-page":"3920","DOI":"10.1073\/pnas.0509592103","volume":"103","author":"T Inagaki","year":"2006","unstructured":"Inagaki, T. et al. Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc. Natl Acad. Sci. USA 103, 3920\u20133925 (2006).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"404_CR151","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.2337\/db06-1642","volume":"56","author":"T Jiang","year":"2007","unstructured":"Jiang, T. et al. Farnesoid X receptor modulates renal lipid metabolism, fibrosis, and diabetic nephropathy. Diabetes 56, 2485\u20132493 (2007).","journal-title":"Diabetes"},{"key":"404_CR152","volume":"7","author":"Z Gai","year":"2017","unstructured":"Gai, Z. et al. Farnesoid X receptor activation protects the kidney from ischemia-reperfusion damage. Sci. Rep. 7, 9815 (2017).","journal-title":"Sci. Rep."},{"key":"404_CR153","volume":"6","author":"K Zhao","year":"2016","unstructured":"Zhao, K. et al. Activation of FXR protects against renal fibrosis via suppressing Smad3 expression. Sci. Rep. 6, 37234 (2016).","journal-title":"Sci. Rep."},{"key":"404_CR154","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1124\/mol.106.023820","volume":"70","author":"G Rizzo","year":"2006","unstructured":"Rizzo, G. et al. The farnesoid X receptor promotes adipocyte differentiation and regulates adipose cell function in vivo. Mol. Pharmacol. 70, 1164\u20131173 (2006).","journal-title":"Mol. Pharmacol."},{"key":"404_CR155","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0114393","volume":"9","author":"RM Nijmeijer","year":"2014","unstructured":"Nijmeijer, R. M. et al. Impact of global Fxr deficiency on experimental acute pancreatitis and genetic variation in the FXR locus in human acute pancreatitis. PLoS ONE 9, e114393 (2014).","journal-title":"PLoS ONE"},{"key":"404_CR156","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1016\/j.febslet.2010.04.068","volume":"584","author":"IR Popescu","year":"2010","unstructured":"Popescu, I. R. et al. The nuclear receptor FXR is expressed in pancreatic \u03b2-cells and protects human islets from lipotoxicity. FEBS Lett. 584, 2845\u20132851 (2010).","journal-title":"FEBS Lett."},{"key":"404_CR157","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.2174\/0929867324666170124151940","volume":"24","author":"D Moris","year":"2017","unstructured":"Moris, D., Giaginis, C., Tsourouflis, G. & Theocharis, S. Farnesoid-X receptor (FXR) as a promising pharmaceutical target in atherosclerosis. Curr. Med. Chem. 24, 1147\u20131157 (2017).","journal-title":"Curr. Med. Chem."},{"key":"404_CR158","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/ClinicalTrials.gov\/show\/NCT04270682 (2020)."},{"key":"404_CR159","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1172\/JCI18945","volume":"112","author":"YP Liu","year":"2003","unstructured":"Liu, Y. P. et al. Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis. J. Clin. Invest. 112, 1678\u20131687 (2003).","journal-title":"J. Clin. Invest."},{"key":"404_CR160","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","volume":"394","author":"ZM Younossi","year":"2019","unstructured":"Younossi, Z. M. et al. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 394, 2184\u20132196 (2019).","journal-title":"Lancet"},{"key":"404_CR161","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/ClinicalTrials.gov\/show\/NCT02855164 (2020)."},{"key":"404_CR162","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/ClinicalTrials.gov\/show\/NCT02516605 (2019)."},{"key":"404_CR163","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/ClinicalTrials.gov\/show\/NCT02913105 (2021)."},{"key":"404_CR164","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/ClinicalTrials.gov\/show\/NCT03804879 (2020)"},{"key":"404_CR165","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1053\/j.gastro.2018.06.038","volume":"155","author":"A Al-Khaifi","year":"2018","unstructured":"Al-Khaifi, A., Rudling, M. & Angelin, B. An FXR agonist reduces bile acid synthesis independently of increases in FGF19 in healthy volunteers. Gastroenterology 155, 1012\u20131016 (2018).","journal-title":"Gastroenterology"},{"key":"404_CR166","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/ClinicalTrials.gov\/show\/NCT01999101 (2016)."},{"key":"404_CR167","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/hep.31205","volume":"72","author":"K Patel","year":"2020","unstructured":"Patel, K. et al. Cilofexor, a nonsteroidal FXR agonist, in patients with noncirrhotic NASH: a phase 2 randomized controlled trial. Hepatology 72, 58\u201371 (2020).","journal-title":"Hepatology"},{"key":"404_CR168","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejim.2017.06.020","volume":"47","author":"A Floreani","year":"2018","unstructured":"Floreani, A. & Mangini, C. Primary biliary cholangitis: old and novel therapy. Eur. J. Intern. Med. 47, 1\u20135 (2018).","journal-title":"Eur. J. Intern. Med."}],"container-title":["Nature Reviews Gastroenterology & Hepatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41575-020-00404-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41575-020-00404-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41575-020-00404-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T17:52:30Z","timestamp":1684605150000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41575-020-00404-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,10]]},"references-count":168,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["404"],"URL":"https:\/\/doi.org\/10.1038\/s41575-020-00404-2","relation":{},"ISSN":["1759-5045","1759-5053"],"issn-type":[{"value":"1759-5045","type":"print"},{"value":"1759-5053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,10]]},"assertion":[{"value":"14 December 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}